Skip to main content
Neuropsychopharmacology logoLink to Neuropsychopharmacology
. 2016 Jun 10;41(8):2188. doi: 10.1038/npp.2016.46

Atomoxetine Enhances Connectivity of Prefrontal Networks in Parkinson's Disease

Robin J Borchert, Timothy Rittman, Luca Passamonti, Zheng Ye, Saber Sami, Simon P Jones, Cristina Nombela, Patricia Vázquez Rodríguez, Deniz Vatansever, Charlotte L Rae, Laura E Hughes, Trevor W Robbins, James B Rowe
PMCID: PMC4908653  PMID: 27282105

Correction to: Neuropsychopharmacology advance online publication, 2 March 2016; doi:10.1038/npp.2016.18

Following the publication of this paper, the authors have changed the Funding and Disclosure section to read as follows:

This work was funded by the Wellcome trust (103838), Parkinson's UK, National Institute for Health Research's Cambridge Biomedical Research Centre and the Medical Research Council (MC_US_A060_0016 and RG62761), and the James F McDonnell Foundation (21st century science initiative on Understanding Human Cognition). The BCNI is supported by a joint award from the Wellcome Trust and Medical Research Council.

TWR reported receiving grants from GlaxoSmithKline, Lilly and Lundbeck; consulting fees from Merck, GlaxoSmithKline, Lundbeck, Lilly, Teva, Shire, Otsuka, and Cambridge cognition; honorarium from Springer-Verlag for Psychopharmacology editorial duties; and payments from Cambridge Cognition for Cambridge Neuropsychological Test Automated Battery (CANTAB). The authors declare no conflict of interest.


Articles from Neuropsychopharmacology are provided here courtesy of Nature Publishing Group

RESOURCES